[go: up one dir, main page]

MX2016008418A - Metodos y reactivos para el radiomarcaje. - Google Patents

Metodos y reactivos para el radiomarcaje.

Info

Publication number
MX2016008418A
MX2016008418A MX2016008418A MX2016008418A MX2016008418A MX 2016008418 A MX2016008418 A MX 2016008418A MX 2016008418 A MX2016008418 A MX 2016008418A MX 2016008418 A MX2016008418 A MX 2016008418A MX 2016008418 A MX2016008418 A MX 2016008418A
Authority
MX
Mexico
Prior art keywords
methods
present
provides
radiolabeling
compounds
Prior art date
Application number
MX2016008418A
Other languages
English (en)
Inventor
Taldone Tony
O Ochiana Stefan
Pillarsetty Nagavarakishore
Chiosis Gabriela
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2016008418A publication Critical patent/MX2016008418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona métodos para radiomarcar compuestos útiles como inhibidores de Hsp90. La presente invención también proporciona intermedios útiles en tales métodos, y composiciones de compuestos radiomarcados. La presente invención proporciona, entre otros, nuevos métodos para la síntesis de compuestos radiomarcados. En ciertas modalidades, la presente invención proporciona compuestos de fórmula I.
MX2016008418A 2013-12-23 2014-12-23 Metodos y reactivos para el radiomarcaje. MX2016008418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919901P 2013-12-23 2013-12-23
PCT/US2014/072090 WO2015138039A1 (en) 2013-12-23 2014-12-23 Methods and reagents for radiolabeling

Publications (1)

Publication Number Publication Date
MX2016008418A true MX2016008418A (es) 2017-01-11

Family

ID=54072256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008418A MX2016008418A (es) 2013-12-23 2014-12-23 Metodos y reactivos para el radiomarcaje.

Country Status (13)

Country Link
US (3) US9994573B2 (es)
EP (1) EP3086792B1 (es)
JP (1) JP6491214B2 (es)
KR (1) KR102325454B1 (es)
CN (1) CN106456645B (es)
AU (1) AU2014386214B2 (es)
BR (1) BR112016014758A8 (es)
CA (1) CA2934850C (es)
IL (1) IL246403B (es)
MX (1) MX2016008418A (es)
RU (1) RU2016128528A (es)
TW (1) TWI673279B (es)
WO (1) WO2015138039A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CA2961499A1 (en) * 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
US10812036B2 (en) * 2015-06-30 2020-10-20 Hitachi Kokusai Electric Inc. Matching box and matching method
KR102175125B1 (ko) * 2018-12-28 2020-11-05 울산과학기술원 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물
WO2022182731A1 (en) * 2021-02-24 2022-09-01 Samus Therapeutics, Inc. Sn-labeling and radiolabeling of epichaperome inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2005012482A2 (en) 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
NZ572600A (en) 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US8324240B2 (en) 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
JP2011503206A (ja) 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
KR101906568B1 (ko) 2009-10-07 2018-10-10 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
WO2012149493A2 (en) 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
KR102025142B1 (ko) * 2011-07-08 2019-09-26 슬로안-케테링인스티튜트퍼캔서리서치 표지된 ｈｓｐ90 억제제의 용도
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EA201690406A1 (ru) * 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
AU2016336351A1 (en) 2015-10-05 2018-05-10 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
US20180251461A1 (en) 2018-09-06
BR112016014758A8 (pt) 2020-06-02
US20200017502A1 (en) 2020-01-16
TW201609773A (zh) 2016-03-16
CN106456645A (zh) 2017-02-22
US10329293B2 (en) 2019-06-25
KR20160101186A (ko) 2016-08-24
US20170029426A1 (en) 2017-02-02
CN106456645B (zh) 2021-03-23
RU2016128528A (ru) 2018-01-30
EP3086792A1 (en) 2016-11-02
AU2014386214B2 (en) 2020-05-21
US9994573B2 (en) 2018-06-12
JP6491214B2 (ja) 2019-03-27
AU2014386214A1 (en) 2016-07-14
KR102325454B1 (ko) 2021-11-16
US10793570B2 (en) 2020-10-06
IL246403B (en) 2020-08-31
JP2017502039A (ja) 2017-01-19
EP3086792A4 (en) 2017-05-24
EP3086792B1 (en) 2022-10-12
TWI673279B (zh) 2019-10-01
WO2015138039A1 (en) 2015-09-17
CA2934850A1 (en) 2015-09-17
IL246403A0 (en) 2016-08-31
CA2934850C (en) 2022-12-06
BR112016014758A2 (es) 2017-08-08

Similar Documents

Publication Publication Date Title
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
TN2015000420A1 (en) Novel compounds and compositions for inhibition of fasn
PH12015500263A1 (en) New bicyclic derivatives
MX381456B (es) Regulador de ph de transduccion.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EA201590887A1 (ru) Композиция
PH12014500814A1 (en) New aryl-quinoline derivatives
MY176465A (en) Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines
MX2016008418A (es) Metodos y reactivos para el radiomarcaje.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
PH12014501781A1 (en) Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201590729A1 (ru) Производные 3,4-дизамещенного оксазолидинона и их применение в качестве ингибиторов кальцийактивируемых калиевых каналов
IN2014DN10135A (es)
MX391523B (es) Intermediarios y metodos para sintetizar derivados de calicheamicina
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.
MX2015009377A (es) Compuestos radiomarcados.
IN2013CH05394A (es)
NZ751449A (en) Novel compounds and compositions for inhibition of fasn